Anemia Management in CKD Stage 3b Patients
Diagnosis and Evaluation
- The National Kidney Foundation recommends that anemia be diagnosed in CKD stage 3b patients with hemoglobin <12.0 g/dL in females or <13.5 g/dL in males 1, 2
- Anemia prevalence increases significantly when GFR falls below 60 mL/min/1.73 m² (stage 3 CKD) 1, 2
Iron Status Assessment
- The American Journal of Kidney Diseases suggests checking transferrin saturation (TSAT) and serum ferritin immediately before initiating any anemia therapy 3, 4
- Target iron parameters are TSAT ≥20% and ferritin ≥100 ng/mL 3, 5, 6
Iron Supplementation Strategy
- For CKD stage 3b (non-dialysis) patients, if TSAT ≤30% and ferritin ≤500 ng/mL, initiate a trial of oral iron at 200 mg elemental iron daily for adults 3, 4
- Alternatively, IV iron can be used (500-1,000 mg iron dextran as single infusion after 25 mg test dose) if oral iron fails or is not tolerated 3, 6
ESA Therapy Decision Algorithm
- The Kidney International guidelines state that ESA therapy should not be initiated at hemoglobin 11.1 g/dL 7, 8
- For adult CKD non-dialysis patients with Hb ≥10.0 g/dL, ESA therapy should not be routinely initiated 7, 8
- ESA initiation for Hb <10.0 g/dL should be individualized based on rate of Hb decline, response to iron therapy, transfusion risk, ESA therapy risks, and anemia symptoms 7, 8
Monitoring Schedule
- The Kidney International guidelines recommend measuring hemoglobin at least every 3 months in CKD stage 3 patients not on ESA therapy 4
- More frequent monitoring (monthly) is needed during iron therapy initiation or if Hb is declining 1, 2
- Check TSAT and ferritin every 3 months during treatment 3, 4
Target Hemoglobin Goals
- If ESA therapy becomes necessary, target Hb 11-11.5 g/dL 7, 8
- Do not target Hb >11.5 g/dL routinely due to increased cardiovascular risks 7, 8
- Never intentionally increase Hb above 13 g/dL with ESA therapy 7, 8